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ABSTRACT: This contribution highlights eﬀorts by the International Union of Basic and Clinical Pharmacology (IUPHAR)
Nomenclature Committee (NC-IUPHAR) to classify human receptors and ion channels, to document their properties, and to
recommend ligands that are useful for characterization. This eﬀort has inspired the creation of an online database (IUPHAR-DB),
which is intended to provide free information to all scientists, summarized from primary literature by experts.
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The recent explosion in data generation from high-through-put studies (ligand-screening, genomic and proteomic data
sets) as well as the sheer volume of scientiﬁc literature represents
an enormous, largely untapped data mine relevant to drug
discovery and drug target research in neuroscience. Maximizing
the beneﬁts of the information requires researchers to keep
abreast of new developments in an increasingly complex area and
to quickly extract their meaning. There is a fundamental need for
resources which distill available data into an easy-to-digest
format, identifying the most important information, standardiz-
ing it, integrating it with other, often disparate, data sources,
placing it in context, and making authoritative recommendations
about the data. This time intensive process forms a signiﬁcant
part of what is now referred to as “data curation”, which we
believe is essential to building trusted public scientiﬁc informa-
tion resources.
In today’s interdisciplinary information age, basic pharmaco-
logical research can no longer be considered separate from, but
must form an integral part of, the rational drug discovery cycle.
Discoveries from basic science are essential inputs to the drug
development process, and pharmaceutical companies are in-
creasingly recognizing the value of sustained academic and
collaborative precompetitive research into drug targets.1 Such a
multidisciplinary, translational approach to pharmacology and
drug discovery would beneﬁt from having community-developed
public-domain knowledge bases and repositories for information
from literature.2 These would ideally provide details and recom-
mendations on all factors that may inﬂuence drug targets and
their interactions with ligand molecules, at species, individual,
and cellular levels. This would expand the available target
information, deﬁning drug targets in their biological contexts
and increasing awareness of the range of targets which interact
with each compound. Large data warehouses of chemical in-
formation such as PubChem3 and ChemSpider4 and medicinal
chemistry databases such as ChEMBL5 exist to catalog the vast
chemistry space. However, there remains a need for focused public-
domain resources to identify the most commonly used chemical
tools and drugs and connect them to data on biological targets and
clinical relevance.
The International Union of Basic and Clinical Pharmacology
(IUPHAR) Committee on Receptor Nomenclature and Drug
Classiﬁcation (NC-IUPHAR), a voluntary, nonproﬁt associa-
tion, issues guidelines for the classiﬁcation and naming of
human receptors and ion channels.6 Their mission is to provide
recommendations for pharmacology (e.g., refs 7 and 8), to
distill relevant data from literature on receptors and their
properties, to disseminate the information publicly, and to
provide a platform for experts to discuss current issues. Their
work is communicated through an online database, IUPHAR-
DB (http://www.iuphar-db.org), which is intended to provide
free information on human drug targets to scientists anywhere
in the world.9 IUPHAR-DB is driven by an expert curation
model relying on NC-IUPHAR’s >60 subcommittees of inter-
national experts (numbering ∼700 individuals from academia
and industry).
By engaging experts in the data curation process, NC-IU-
PHAR is trying to address one of the signiﬁcant issues in drug
discovery today: that of identifying the repertoire of human drug
targets. In this endeavor, it is essential to recognize all of the
factors that can inﬂuence receptor structure, function, expres-
sion, and pharmacology. Drug targets are deﬁned in a broader
sense than “single gene products” to encompass other variables
which aﬀect function. Factors that contribute to the deﬁnition of
a unique target include the particular sequence variant(s) pre-
sent; speciﬁc tissue and subcellular location; a given combination
of subunits, cofactors, and ligands; presence of post-translational
modiﬁcations; pathophysiological context; and the downstream
signaling pathway being initiated. These can vary across species,
individual, tissue, developmental stage, and disease to give rise to
a much more diverse range of potential drug targets than are
speciﬁed at the gene level. Moreover, there is increasing evidence
that ligand selection can inﬂuence the speciﬁc downstream
pathways aﬀected and therefore the functions mediated (for a
recent review, see ref 10).
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IUPHAR-DB has been developed with these principles
strongly in mind. Thus, as the concept of “drug target” gradually
evolves, so the database is constantly evaluated, revised, and
shaped by the scientiﬁc community. Presently, the database
includes the products of over 600 human genes (and their rodent
orthologs) from four superfamilies: G protein-coupled receptors
(GPCRs), nuclear hormone receptors (NHRs), and voltage- and
ligand-gated ion channels.11 Members of these protein families
constitute the targets of at least a third of licensed therapeutic
drugs, as well as several drugs of abuse.12 IUPHAR-DB also lists
proteins with sequence/structural similarities to known recep-
tors but which do not yet have identiﬁed endogenous ligands
(such as orphan GPCRs), which may nonetheless be of interest
as drug targets. The NC-IUPHAR Evolving Pharmacology
subcommittee debates the evidence for and issues guidelines
on the acceptance of ligandreceptor pairings, with updates
broadcast on the Web site.
Information provided on target proteins in IUPHAR-DB covers
a diversity of subjects, including the NC-IUPHAR recommended
nomenclature, other names found in literature, details of struc-
ture, function, expression, clinical relevance, genetic, and splice
variants, genetically modiﬁed mouse models, ion channel conduc-
tance, GPCR signaling mechanisms, NHR target genes, natural
ligands, experimental drug tools, and functional assays. Full text
search functionality is provided. Most importantly, all data are
linked to their primary references in PubMed as well as to further
sources of information, for example, UniProt,13 Ensembl,14 Entrez
Gene and Protein,15 OMIM,16 and ChEMBL.
Central to the target concept is the need for appropriate
knowledge and recommendations on endogenous and experi-
mental ligands/drugs. This includes documenting their actions
(e.g., agonist, antagonist, allosteric regulator, ion channel block-
er, or gating inhibitor) and their wider activity spectrum (cross-
reactivity and oﬀ-target eﬀects), which is of interest to both drug
discovery and basic experimental science. An example of how this
information is displayed for the β2-adrenoceptor can be seen in
Figure 1.
IUPHAR-DB provides curated sets of compounds, their
pharmacological actions, and activity data represented as IC50,
Ki, Kd, and EC50 (as appropriate), linked to their primary
literature sources. These include ligands commonly or histori-
cally used in experiments, approved drugs, and radio-labeled
probes (including 1750 small molecules, 900 peptides, and 80
natural products). Each ligand is represented (where possible) by
a common name, synonyms, SMILES strings containing chiral
speciﬁcations, InChI and InChI Keys, systematic names, and
two-dimensional (2D) images. Figure 2 is a screenshot of part of
a ligand page showing the bioactivity data and physicochemical
properties of the drug olanzapine. Various calculated physico-
chemical properties are provided, including the ﬁve Lipinski
Figure 1. Part of the β2-adrenoceptor database page showing the 3D structure along with an expert-selected set of receptor agonists.
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“drug-likeness” measures:17 polar surface area, predicted LogP,
molecular weight, and number of hydrogen bond donors and
acceptors. Integrated links provide access to supplementary
knowledge in other online resources with biological, chemical,
and structural information (e.g., DrugBank,18 RCSB Protein
Data Bank,19 PubChem, and ChEMBL).
Figure 3 shows that, in terms of their physicochemical proﬁles,
the majority of small molecule compounds in the database obey
the Lipinski drug-likeness rules, with greater than 80% of the
compounds breaking fewer than two rules.
IUPHAR-DB is widely used as a quick online reference
resource for neuroscientists looking for information relevant to
pharmacology and drug discovery. Other useful features include
the ability to launch a chemical editor and search tool (from the
interactive ligand image or from a link on the page sidebar),
allowing structures to be modiﬁed and used as queries for
structure-based searching. This is the ﬁrst of a series of planned
improvements designed to make the information more accessi-
ble. Ongoing work aims to curate the IUPHAR-DB peptide
ligands, which remain under-represented in terms of structural
properties and searchability.We also intend to broaden the target
coverage and to enhance chemical information by providing
expert-recommended sets of chemical tools with optimum
proﬁles for practical use in in vitro and in vivo test systems.
Figure 2. Part of the ligand page for the drug olanzapine, displaying the calculated physicochemical properties and a summary of the literature reporting
its binding activity at human GPCRs.
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